跳到正文
BioProcess International · 工艺与质量· Christine Quern·AI 评分59

行业专家分析连续色谱在单克隆抗体纯化中的应用与挑战

Reimagining mAb Purification Through Continuous Chromatography

AI 导读

多位下游工艺、连续色谱与自动化专家接受采访时分析连续色谱在单克隆抗体纯化中的应用,认为最大的经济收益来自强化灌流上游与连续下游纯化的整合,混合模式比全流程连续更易落地。

正文 · 原文

24-10-Quern-C-P1.png

https://stock.adobe.com

It’s a complicated balancing act. Biopharmaceutical companies continue to evaluate new approaches to produce monoclonal antibodies (mAbs) more efficiently, sustainably, and flexibly within increasingly complex product portfolios while simultaneously reducing costs and accelerating development timelines.

Those imperatives are driving interest in continuous manufacturing, in which product continuously flows through sequential upstream and downstream unit operations with minimal hold times, enabling more efficient, intensified, and automated manufacturing than can be achieved through traditional batch processing. Although the vision of fully integrated end-to-end continuous manufacturing has existed for years, implementation has accelerated more recently as enabling technologies such as continuous chromatography have matured.

Continuous chromatography is a method by which drug manufacturers can intensify purification processes, improve resin use, reduce required facility footprints, and integrate downstream operations with high-yield, upstream manufacturing processes. In parallel, advances in automation, process analytical technologies (PATs), digitalization, and real-time control strategies are making continuous purification more practical than ever.

Related:High-Performance Liquid Chromatography Continues To Set the Pace for Biopharmaceutical Analytics

In this article, I explore opportunities and challenges that shape adoption of continuous chromatography for mAbs. Experts in downstream processing, continuous chromatography, automation, and manufacturing operations share their perspectives on the benefits of this approach, implementation strategies, and the future direction of the field.

Continuous Manufacturing Matters for mAbs

Interest in continuous manufacturing has increased steadily across the biopharmaceutical sector, although adoption has been slower compared with that of other industries. Chris Hwang (founder of Quantum Leap CMC Consulting and former chief technology officer of Transcenta) believes that the industry has entered a new phase of acceptance. According to Hwang, the trajectory resembles the the biopharmaceutical industry’s previous adoption of single-use technologies, which took well over a decade to become mainstream.

Kevin Brower (global head of purification development at Sanofi) sees a similar transition occurring across the industry. He notes a recent downstream processing conference at which discussions centered on how to implement continuous processes. That framing, he observes, contrasts with that at prior events, which focused on whether that strategy should be adopted. Several factors are driving that shift, such as increases in upstream cell culture titers. As upstream productivity rises, downstream purification systems designed around historical titers struggle to keep pace. Larger columns and facility footprints often are required to keep pace if traditional batch chromatography approaches are maintained.

Related:Membrane Chromatography: Helping Downstream Processing To Follow Upstream Innovation

Economic pressure is another driver. Hwang explains that global pricing pressures, particularly in emerging markets, are forcing manufacturers to rethink cost structures. Importantly, experts emphasize that the largest economic gains come not from downstream intensification alone, but from integration between intensified upstream perfusion and continuous downstream purification. With sufficient automation and control to increase throughput, continuous downstream systems enable facilities to process high amounts of mAb solutions without proportionally increasing infrastructure.

The result is a more productive and flexible manufacturing model. Instead of relying on massive stainless-steel facilities with fixed capacity, manufacturers can scale out modular single-use production trains as needed. Hwang noted that scaling through “numbering up” identical trains can simplify validation compared with traditional large-scale expansion. At Transcenta, intensified upstream perfusion combined with intensified downstream processing is projected to reduce manufacturing costs by as much as 50%.

Related:Simulation-Aided Development of Multicolumn Chromatography Processes for Protein-Based Vaccine Production

Chromatography as a Critical Enabler

Chromatography remains central to downstream mAb purification as it delivers the selectivity and impurity clearance necessary to achieve product quality targets. However, it is also one of the most resource-intensive and time-consuming downstream operations.

Margit Holzer (scientific director at Ulysse Consult) notes that chromatography steps are often expensive and inherently limiting because resin capacity is finite and columns must be cycled repeatedly. Affinity resins such as those based on protein A are particularly costly, making improved resin utilization highly attractive from an economic standpoint.

In conventional batch chromatography, a single column cycles across loading, washing, elution, regeneration, and equilibration phases. As a result, product must be loaded intermittently onto the resin, reducing overall productivity. By contrast, multicolumn chromatography (MCC) distributes operations across multiple smaller columns that operate in parallel or in staggered cycles, improving resin utilization and overall process productivity. While one column is loading product, another is washing or regenerating. Brower describes MCC as a “batch merry-go-round” that improves overall equipment use. MCC allows manufacturers to use smaller columns more efficiently and thereby dramatically reduce total resin volumes across all manufacturing scale. Joel Ngoje, downstream manufacturing science and technology (MSAT) engineer at MilliporeSigma, describes a process using three 1-L columns to process material that traditionally would have required ≈60 L of resin.

With batch chromatography, columns are underloaded intentionally to minimize product breakthrough and prevent loss of target protein in the flowthrough. As a result, the effective loading per cycle is typically limited to around 60–70% of the dynamic binding capacity (DBC) at 10% breakthrough, notes Nilanjan Pal Chowdhury (application lead for process solutions at Merck KGaA). In batch mode, chromatographic unit operations generally rely on relatively long residence times to maximize binding of a target molecule within a single cycle.

A primary way that some MCC systems improve utilization is through a shared-loading configuration, in which product breakthrough from a primary column is captured by a serially connected secondary column. In systems that employ shared loading, resin utilization can be significantly increased because material that would otherwise be lost is captured on a downstream column. Because MCC systems can tolerate shorter residence times without sacrificing capture efficiency, they offer greater operational flexibility, higher resin utilization, and wider operating ranges than conventional batch chromatography.

Chowdhury notes that membrane chromatography (MC) offers excellent reduction in process costs by shortening cycle time while maintaining comparable yield and impurity clearance. Although MCC becomes an easy choice for large scale volumes, MC is particularly helpful for early stage and clinical-scale biomanufacturing.

In addition to MCC, continuous chromatography encompasses a range of operating approaches, such as periodic counter-current chromatography (PCC), sequential multicolumn chromatography (SMCC), simulated moving bed (SMB) systems, and multicolumn countercurrent solvent gradient purification (MCSGP). Those approaches are designed to improve resin utilization, productivity, separation efficiency, and process intensification compared with conventional batch chromatography.

Although more advanced continuous chromatography systems can deliver additional efficiency gains, the added complexity must be carefully managed. Irina Ramos, who led development of intensified downstream processing systems during her time at AstraZeneca, expresses skepticism about highly complex SMB systems. She argues that associated good manufacturing practice (GMP) control strategies and failure-mode analyses, although scientifically elegant, can become prohibitively complicated. Instead, Ramos favors simpler dual- or triple-column automated approaches that provide substantial intensification benefits while minimizing operational risk. She also notes that these systems are often easier to develop at bench scale, transfer into manufacturing, and scale-up.

A consideration for continuous chromatography is the need for tighter integration with upstream perfusion processes. Instead of waiting for a complete harvest batch before purification begins, downstream capture can occur continuously as material is harvested from a bioreactor. Holzer notes that this integration enables smaller systems overall because flow rates can remain lower and more constant than what would be needed for larger setups. Early processing also minimizes hold times that can diminish product stability.

Buffer management is another critical consideration in continuous chromatography design. Although continuous systems do not necessarily reduce total buffer demand, they can eliminate inefficiencies associated with solution preparation, transfers, flushes, and hold-up volumes. Victor Melendez-Colon (head of applications R&D at Avantor) explains that continuous feeding strategies help maximize operational utilization while reducing waste associated with the readiness of unit operations and intermediate handling steps.

At the same time, continuous systems are driving greater focus on sustainability. Reduced resin consumption, smaller facility footprints, and more efficient buffer management all contribute to improved environmental performance. Fabian Schmidt (data engineer for sustainability at Merck KGaA) notes that sustainability is becoming an increasingly important part of industry discussions surrounding continuous manufacturing.

Continuous Chromatography as Part of a Hybrid Approach

Despite the benefits of implementing a fully continuous process, that may not be the best option for achieving the desired benefits, according to the experts interviewed for this article. They described the challenges and highlighted how a hybrid approach that includes continuous chromatography is a viable alternative.

One of the biggest challenges of continuous processing is mechanical and digital synchronization across integrated unit operations. Continuous systems require coordination among upstream perfusion, clarification, chromatography, viral inactivation, filtration, and buffer management systems.

Holzer identifies contamination control, bioburden management, and product quality assurance as some of the most critical concerns in integrated continuous systems. Clarification interfaces are especially important. In continuous perfusion systems, technologies such as alternating-tangential flow (ATF) filtration commonly are used to separate cells continuously from product-containing supernatants before downstream purification. Maintaining uninterrupted flow requires robust filtration trains and switching strategies that allow systems to transition seamlessly between filters during operation while protecting against contamination and minimizing the impact on product quality.

Automation complexity also increases substantially as more unit operations become integrated. Beth Fahnestock (director of new product innovation at Avantor) emphasizes that continuous operations amplify the operational consequences of even small disruptions. Continuous workflows require uninterrupted coordination across buffers, pumps, sensors, and transfer systems.

Melendez-Colon describes that challenge as a manufacturing “traffic jam,” in which problems in one unit operation quickly propagate to subsequent operations if redundancy and contingency planning are not built into the process design. As a result, continuous systems may incorporate redundant vessels, columns, pumps, and transfer flow paths enabling the capability to rapidly swap in new components and minimize operational interruptions.

In light of such considerations, companies might pursue hybrid continuous strategies rather than fully end-to-end continuous processes. In hybrid approaches, selected unit operations such as protein A capture might operate continuously while other steps remain batch-based. Brower advises against attempting fully continuous manufacturing immediately, noting that hybrid approaches often provide a more practical entry point. Hwang describes Transcenta’s continuous manufacturing strategy as a hybrid approach that combines intensified perfusion upstream with continuous protein A capture and a downstream process incorporating both batch operations and an integrated, automated flow-through polishing (FTP) train. By de-bottlenecking downstream operations while minimizing downstream footprints and complexities, hybrid continuous solutions preserve floor space for additional bioreactor capacity and enables greater facility throughput, a key driver of lower cost of goods (CoG).

Retrofit feasibility is another important consideration. Although greenfield facilities offer greater design flexibility than brownfield ones do, experts believe many existing facilities can adopt at least partial continuous strategies. Brower note that several organizations are already incorporating multicolumn technologies into retrofits as they expand or de-bottleneck operations.

Single-use technologies also are making hybrid and continuous implementation more practical by reducing cleaning requirements and increasing operational flexibility through the execution of efficient changeover procedures. For example, many newer MCC systems are designed around disposable flow paths that simplify changeovers and reduce cleaning validation burdens, making them especially attractive for contract development and manufacturing organizations (CDMOs) and multiproduct facilities.

Still, experts stress that successful implementation requires more than simply installing new equipment. Organizations must also adapt their standard operating procedures, facility operation logistics, manufacturing culture, workforce training, and data infrastructure to support highly automated, long-duration operations.

Data, Automation, and Control Strategies

Automation and digitalization are foundational to successful continuous chromatography. Unlike traditional batch processing, in which operators manually monitor discrete process steps, continuous systems require real-time visibility into process performance across extended operational periods. Brower noted that operators often appreciate the increased automation because it reduces manual intervention and simplifies operations.

Modern continuous systems increasingly rely on advanced PAT tools, in-line sensors, and real-time monitoring platforms. These tools allow manufacturers to dynamically monitor loading behavior, resin performance, flow rates, conductivity, pH, ultraviolet (UV) absorbance, and other critical process parameters during operation. Breakthrough detection systems are essential for maximizing resin utilization. Rather than loading for a predefined volume, systems dynamically monitor column saturation and automatically switch loading between columns when breakthrough is detected. Those control capabilities become especially important during long-duration runs, where resin performance may gradually change over time. Sensors and automation systems can quickly identify shifts in binding behavior and adjust operations accordingly. The loading can be directed to the next column as needed, notes Chowdhury.

In-line sampling technologies are also important. Traditional quality testing approaches that rely on off-line sampling and delayed analysis are poorly suited for continuous operations, where material moves relatively quickly through multiple unit operations over extended periods of time. Off-line measurement and delayed analytical monitoring may prevent critical timely interventions. Ngobe describes systems capable of automatically collecting and transferring samples to quality control (QC) laboratories while the process continues uninterrupted, allowing QC data to be available by the end of extended campaigns.

As continuous systems become more integrated, data management requirements increase significantly. Manufacturers must aggregate and analyze large volumes of process data while maintaining robust traceability and ensuring that deviations can be rapidly identified and addressed.

Several experts point to predictive analytics and advanced modeling as important future directions. Ramos emphasizes the value of systems that identify trends before failures occur, such as detecting gradual declines in column performance or identifying tubing and pressure anomalies before they affect product quality.

Melendez-Colon also emphasizes the increasing significance of in-line monitoring technologies in supporting continuous release strategies. In-line pH, conductivity, and other essential PAT tools facilitate the prediction of atypical process trends, enabling proactive interventions that minimize delays inherent to traditional methodologies requiring offline testing and foster real-time, responsive process control. Ultimately, experts stress that automation itself is not the goal. Rather, automation enables manufacturers to maintain a robust state of control across increasingly complex and highly intensified manufacturing operations.

Regulatory and Validation Considerations

Regulatory attitudes toward continuous manufacturing have evolved significantly over the past decade. Several experts noted that regulators are now substantially more comfortable with continuous technologies than they were in earlier years, particularly following publication of ICH Q13 guidance on continuous manufacturing (1). The guideline provides manufacturers with a clearer framework for implementing continuous processes, including expectations around process control strategies, traceability, state of control, and lot definition. Holzer describes regulatory interactions as increasingly collaborative, with agencies eager to understand how manufacturers are approaching continuous operations.

Ramos notes that regulators care less about the specific technology used and more about whether the process is robustly controlled to deliver product quality that meets specifications. Still, continuous systems introduce important validation challenges. Compared with traditional batch manufacturing, continuous operations may involve longer run times, more interconnected equipment, and greater reliance on automation and data systems. Manufacturers must demonstrate that processes remain controlled throughout extended campaigns and that disturbances can be rapidly detected and mitigated.

Lot definition is a frequently discussed topic in regulatory affairs because material flows uninterrupted through the process and systems, complicating the establishment of distinct batch boundaries. Melendez-Colon observes that manufacturers frequently encounter difficulties in identifying where one lot concludes and another commences, particularly when solutions or intermediates are continuously introduced across multiple operations. Manufacturers may define lots based on processing time windows, material quantities, or specific operating conditions, but traceability remains critical regardless of the strategy used. Despite such complexities, regulatory agencies have become increasingly supportive of continuous manufacturing approaches as industry experience, enabling technologies, and process control strategies have matured.

Future Outlook

Adoption of continuous chromatography and more broad approaches to the overall manufacturing workflow will continue expanding over the next decade. The strongest near-term adoption is likely to occur in intensified hybrid manufacturing platforms that combine upstream perfusion with continuous capture and selected downstream operations.

Future innovation will focus on improved automation platforms, increasingly adaptable single-use systems, better PAT integration, and advanced modeling capabilities. Holzer believes that scheduling optimization may become one of the most impactful developments, allowing facilities to dramatically improve asset utilization simply through smarter coordination of columns, filtration systems, and downstream operations.

Experts also expect modular manufacturing concepts to become increasingly important as companies seek more flexible production capacity. Intensified manufacturing trains could allow organizations to expand capacity incrementally rather than investing in massive, centralized facilities. Ramos believes that intensified continuous systems may ultimately reshape facility design itself by allowing manufacturers to produce commercial quantities using much smaller bioreactors and downstream equipment than have been traditionally required. Advances in chromatography media also are expected to contribute to future gains. Higher-capacity protein A resins, improved membrane adsorbers, and novel stationary phases may further increase throughput while reducing buffer and resin requirements.

Still, several barriers remain. Organizational conservatism, technical complexity, validation burdens, and infrastructure limitations can slow adoption of new approaches to manufacturing. Workforce training will also remain essential as companies adapt to increasingly digital and automated operating models. For companies considering continuous chromatography today, experts consistently recommend starting pragmatically and focusing first on clear business drivers. Hybrid approaches, selective intensification, and manageable operational complexity are likely to define the industry’s near-term path forward.

Ultimately, continuous chromatography is poised to become an increasingly important part of future mAb manufacturing strategies. Whether implemented through hybrid intensification or fully integrated continuous platforms, the technology is helping manufacturers address some of the industry’s most pressing economic, operational, and sustainability challenges.

Reference

1 ICH Q13. Continuous Manufacturing of Drug Substances and Drug Products. International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use: Geneva, Switzerland, 16 November 2022; https://database.ich.org/sites/default/files/ICH_Q13_Step4_Guideline_2022_1116.pdf.

Christine Quern is a freelance writer and founder of CBQ Communications, based in Milford, MA; [email protected]; https://cbqcommunications.com.

This article was published initially in BPI's June 2026 eBook titled "Chromatography: Advanced Materials, Predictive Technologies, and Continuous Operations." Find the complete eBook at https://www.bioprocessintl.com/chromatography/ebook-chromatography-advanced-materials-predictive-technologies-and-continuous-operations.

来源:BioProcess International · 工艺与质量 · bioprocessintl.com